Drugs for Periodontitis, Aggressive, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 25)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ixekizumab |
Approved, Investigational |
Phase 4 |
|
1143503-69-8 |
|
Synonyms:
|
2 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
3 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
4 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
5 |
|
Adalimumab |
Approved, Experimental |
Phase 3 |
|
331731-18-1 |
|
Synonyms:
ADALIMUMAB
ADALIMUMAB (GENETICAL RECOMBINATION)
ADALIMUMAB BETA
adalimumab-adaz
adalimumab-adbm
adalimumab-afzb
adalimumab-atto
adalimumab-bwwd
adalimumab-fkjp
AVT-02
BI695501
CT-P17
D2E7
FKB327
|
FKB-327
GP2017
HLX03
HLX-03
HUMIRA
Humira Pen
IG GAMMA-1 CHAIN C REGION
LU200134
LU-200134
M923
MSB11022
MSB-11022
ZRC3197
ZRC-3197
|
|
6 |
|
Certolizumab pegol |
Approved |
Phase 2, Phase 3 |
|
428863-50-7 |
|
Synonyms:
|
CERTOLIZUMAB PEGOL
CIMZIA
PHA-738144
|
|
7 |
|
Apremilast |
Approved, Investigational |
Phase 3 |
|
608141-41-9 |
10151715 11561674 |
Synonyms:
APREMILAST
APRÉMILAST
APREMILASTUM
CC 10004
CC10004
|
CC-10004
CC-10004|Otezla®
N-{2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULFONYL)ETHYL]-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL}ACETAMIDE
OTEZLA
|
|
8 |
|
Brodalumab |
Approved, Investigational |
Phase 3 |
|
1174395-19-7 |
|
Synonyms:
AMG-827
AMG-827|AMG827|Kyntheum®|Lumicef®|Siliq®
BRODALUMAB
KHK4827
|
|
|
9 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
10 |
|
Immunosuppressive Agents |
|
Phase 2, Phase 3 |
|
|
|
11 |
|
Analgesics |
|
Phase 3 |
|
|
|
12 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
13 |
|
Phosphodiesterase Inhibitors |
|
Phase 3 |
|
|
|
14 |
|
Phosphodiesterase 4 Inhibitors |
|
Phase 3 |
|
|
|
15 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 3 |
|
|
|
16 |
|
Analgesics, Non-Narcotic |
|
Phase 3 |
|
|
|
17 |
|
Anti-Inflammatory Agents |
|
Phase 3 |
|
|
|
18 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
19 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
20 |
|
Antibodies, Monoclonal |
|
Phase 3 |
|
|
|
21 |
|
Antibodies |
|
Phase 3 |
|
|
|
22 |
|
Alefacept |
Approved, Investigational, Withdrawn |
Phase 2 |
|
222535-22-0 |
|
Synonyms:
ALEFACEPT
AMEVIVE
Amevive®|BG 9273|BG 9712|BG-9273|BG-9712|Lfa3Tip
ASP0485
BG-9273
|
BG-9712
LFA-3CD2
LFA3TIP
LFA-3TIP
|
|
23 |
|
Interleukin 1 Receptor Antagonist Protein |
|
Phase 2 |
|
|
|
24 |
|
Lenograstim |
Approved, Investigational |
Phase 1 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
25 |
|
Adjuvants, Immunologic |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show all 38)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis |
Completed |
NCT03942042 |
Phase 4 |
Ixekizumab |
2 |
A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis |
Completed |
NCT02641730 |
Phase 3 |
Guselkumab;Placebo |
3 |
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult Japanese Subjects With Moderate to Severe Palmoplantar Pustulosis |
Completed |
NCT04451720 |
Phase 3 |
Risankizumab;Placebo |
4 |
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Palmoplantar Pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 Weeks of Treatment, Compared to Placebo, and to Assess Long-term Safety, Tolerability, and Efficacy in Subjects With Moderate to Severe Chronic Palmoplantar Pustular Psoriasis - Amended With an Optional Extension Treatment Period of up to a Total of 148 Weeks |
Completed |
NCT02008890 |
Phase 3 |
|
5 |
A Multi-center, Open Label Study of Subcutaneous Secukinumab in Prefilled Syringes as Mono- or Co-therapy to Assess the Efficacy, Safety and Tolerability in Japanese Subjects With Generalized Pustular Psoriasis |
Completed |
NCT01952015 |
Phase 3 |
|
6 |
A Phase 3, Randomized, Open-Label Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis |
Completed |
NCT03022045 |
Phase 3 |
risankizumab |
7 |
A Phase 3, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of CNTO1959 (Guselkumab) in the Treatment of Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis |
Completed |
NCT02343744 |
Phase 3 |
Guselkumab |
8 |
A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis |
Completed |
NCT02533375 |
Phase 3 |
Adalimumab |
9 |
Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis |
Completed |
NCT03051217 |
Phase 2, Phase 3 |
Certolizumab Pegol |
10 |
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Apremilast (AMG 407) in Japanese Subjects With Palmoplantar Pustulosis (PPP) |
Recruiting |
NCT05174065 |
Phase 3 |
Apremilast;Placebo |
11 |
Multi-centre, Open-label, Expanded Access Program of 900mg Intravenous (i.v.) Spesolimab in Patients With Generalized Pustular Psoriasis (GPP) Presenting With a Flare |
Recruiting |
NCT05239039 |
Phase 3 |
spesolimab |
12 |
Multi-centre, Open-label, Expanded Access Trial of Spesolimab i.v. in Patients With Generalized Pustular Psoriasis (GPP) Presenting With a Flare |
Recruiting |
NCT05200247 |
Phase 3 |
spesolimab |
13 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis |
Recruiting |
NCT05352893 |
Phase 3 |
Imsidolimab high dose;Imsidolimab low dose |
14 |
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis |
Recruiting |
NCT05366855 |
Phase 3 |
|
15 |
A Phase 3, Placebo-Controlled, Double-Blind Comparative Study of KHK4827 With an Open-Label Extension in Subjects With Palmoplantar Pustulosis |
Active, not recruiting |
NCT04061252 |
Phase 3 |
KHK4827;Placebo |
16 |
A Pilot Open-Label Study to Evaluate the Safety and Observe the Effectiveness of 16 Weeks of Alefacept in Palmar Plantar Pustulosis (IST 92) |
Completed |
NCT00301002 |
Phase 2 |
Alefacept |
17 |
A Multicenter, Open Label, Single-arm Pilot Study to Evaluate the Efficacy and Safety of Oral Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS) |
Completed |
NCT04572997 |
Phase 2 |
Apremilast |
18 |
Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIb Dose-finding Study to Evaluate Safety and Efficacy of Different Subcutaneous Doses of BI 655130 in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) |
Completed |
NCT04015518 |
Phase 2 |
Spesolimab;Placebo |
19 |
A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis |
Completed |
NCT03633396 |
Phase 2 |
Placebo |
20 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis |
Completed |
NCT03988335 |
Phase 2 |
RIST4721;Placebo |
21 |
A Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic Mechanisms |
Completed |
NCT01794117 |
Phase 2 |
Anakinra |
22 |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody, Following Subcutaneous Administration in Subjects With Palmoplantar Pustulosis |
Completed |
NCT01845987 |
Phase 2 |
Placebo;CNTO 1959 |
23 |
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Palmoplantar Pustulosis in Japan |
Completed |
NCT04057937 |
Phase 2 |
Apremilast;Placebo |
24 |
Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP) |
Completed |
NCT03135548 |
Phase 2 |
Spesolimab (low dose);Placebo;Spesolimab (high dose) |
25 |
Effisayilâ„¢ 1:Multi-center, Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety and Tolerability of a Single Intravenous Dose of Spesolimab (BI 655130) in Patients With Generalized Pustular Psoriasis (GPP) Presenting With an Acute Flare of Moderate to Severe Intensity |
Completed |
NCT03782792 |
Phase 2 |
Spesolimab;Placebo |
26 |
A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis |
Completed |
NCT03619902 |
Phase 2 |
|
27 |
A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis |
Recruiting |
NCT05194839 |
Phase 2 |
RIST4721;Placebo |
28 |
Effisayilâ„¢ ON: An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Spesolimab Treatment in Patients With Generalized Pustular Psoriasis (GPP) |
Recruiting |
NCT03886246 |
Phase 2 |
Spesolimab |
29 |
An Open-label, Long Term Safety Trial of Spesolimab Treatment in Patients With Palmoplantar Pustulosis (PPP) Who Have Completed Previous BI Spesolimab Trials |
Active, not recruiting |
NCT04493424 |
Phase 2 |
Spesolimab |
30 |
Effisayilâ„¢ 2: Multi-center, Randomized, Parallel Group, Double Blind, Placebo Controlled, Phase IIb Dose-finding Study to Evaluate Efficacy and Safety of BI 655130 (Spesolimab) Compared to Placebo in Preventing Generalized Pustular Psoriasis (GPP) Flares in Patients With History of GPP |
Active, not recruiting |
NCT04399837 |
Phase 2 |
Spesolimab;Placebo |
31 |
Double-blind, Randomized, Right-left Study Comparing TEPSO® Socks With Standard Socks in Improving Palmoplantar Pustulosis |
Terminated |
NCT01197989 |
Phase 2 |
|
32 |
A Multicenter, Open-label, 2-regimen, Repeat-dose Study to Assess the Safety and Pharmacokinetics of Intravenous CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis |
Completed |
NCT03972280 |
Phase 1 |
|
33 |
Multi-centre, Open-label, Single Arm, Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacogenomics and Efficacy of a Single Intravenous Dose of BI 655130 in Patients With Active Generalized Pustular Psoriasis. |
Completed |
NCT02978690 |
Phase 1 |
BI655130 |
34 |
Multi-centre, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of HB0034 in Patients Acute Generalized Pustular Psoriasis (GPP) Flare |
Recruiting |
NCT05512598 |
Phase 1 |
HB0034 |
35 |
Pilot Study on Oral Health Status Chairside Mouthrinse Test in Finnish Adolescents and Cost Effectiveness of the Test |
Unknown status |
NCT04139863 |
|
|
36 |
Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence |
Unknown status |
NCT04566471 |
|
|
37 |
The Immune Signature of Palmoplantar Pustulosis |
Completed |
NCT01780857 |
|
|
38 |
Registry of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan |
Recruiting |
NCT04459507 |
|
|
|